Skip to content
Open access

AQP1 Corrects Acinar Cells' Secretion Deficits in Sjögren's Disease.

Aug 2026 · Oral Diseases · 0 citations · 41 references
Medicine

TL;DR

It is demonstrated that AAV2-AQP1 expression enhances fluid secretion in human LSGs and highlight fibrosis-associated loss of glandular parenchyma as a major barrier to therapeutic efficacy.

Abstract

INTRODUCTION Sjögren's disease (SjD) is a systemic autoimmune disease characterized by dry mouth, dry eyes, and profound fatigue. Preclinical studies suggest that AQP1 gene expression in salivary glands corrects salivary hypofunction in preclinical and clinical studies of radiation-induced xerostomia and improves salivary and lacrimal function in SjD mouse models. SUBJECTS AND

Methods

To evaluate its therapeutic potential, we tested AQP1 gene therapy using labial salivary gland (LSG) biopsies from patients with SjD, non-SjD, and healthy volunteer glands (HV).

Results

Ex vivo cultures of LSG lobules were viable, responsive to stimulation, and transducible with an AAV2 vector encoding AQP1. AQP1 expression increased fluid secretion in most samples, with recovery reaching up to 80% of healthy volunteer levels. Baseline transcriptomic analysis identifies 94 genes that correlated with treatment response, with inflammatory and epithelial signature correlating with success and fibrotic signatures with non-response. Histological evaluation confirmed greater fibrosis in non-responding samples. Thus, treatment effects were functionally significant but transcriptionally minimal indicating targeted therapeutic action without altering homeostatic transcription.

Conclusion

These findings demonstrate that AAV2-AQP1 expression enhances fluid secretion in human LSGs and highlight fibrosis-associated loss of glandular parenchyma as a major barrier to therapeutic efficacy.

Read PDF

Similar papers

Sep 2026

Assessment of Salivary Flow Patterns in Sjögren's Disease.

OBJECTIVE Salivary flow may follow a circadian rhythm regulated by clock genes and aquaporins. Because aquaporin 5 dysregulation may contribute to Sjögren's disease, we investigated whether daily unstimulated and stimulated salivary flow patterns differed between participants with Sjögren's disease and healthy controls...

Mouna Alsunni, Matthew D. Finkelman, Mabi L. Singh et al. · 0 citations
Review Open access Sep 2026

Ophthalmic Treatments and Evolving Management of Sjögren’s Disease: An Overview

Ophthalmic SjD management has evolved from palliative lubrication toward a stepwise, mechanism-directed paradigm integrating novel diagnostics, secretomotor stimulation, mechanical protection, and biologic disease modification; dedicated SjD-specific trials remain essential to validate these emerging interventions.

María García Forestier, José Nassar Badillo, Armando L. Oliver · 0 citations
Open access Sep 2026

Neutrophil-Driven Inflammation in Pediatric Chronic Recurrent Multifocal Osteomyelitis.

OBJECTIVE Chronic recurrent multifocal osteomyelitis (CRMO) is a pediatric autoinflammatory bone disease with poorly defined pathophysiology and limited biomarkers. Murine models implicate neutrophils, neutrophil-derived IL-1β, and the adaptor protein PSTPIP2, but direct evidence in human CRMO is lacking. This study ai...

N. Pavliuchenko, P. Daněk, Hana Malcová et al. · 0 citations
Open access Aug 2026

Mepolizumab Modifies Blood Eosinophil Proteome and Transcriptome in Severe Eosinophilic Asthma.

BACKGROUND Mepolizumab, an anti-IL5 monoclonal antibody, effectively reduces exacerbations and improves disease control in severe eosinophilic asthma (SEA). While this treatment rapidly decreases blood eosinophil counts, some patients continue to experience asthma symptoms, suggesting that other features beyond eosinop...

P. Miguéns-Suárez, Sara Vázquez-Mera, L. Martelo-Vidal et al. · 0 citations

Understanding, monitoring, and predicting interferon-driven inflammation in juvenile dermatomyositis

Juvenile dermatomyositis (JDM) is a rare autoimmune disease in which children develop inflammation of the muscles and skin. This can lead to severe muscle weakness and difficulties with walking, swallowing, or even breathing. Unfortunately, current treatments are not effective enough for around half of children with JD...

Saskia R. Veldkamp · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.